Free Trial
NYSE:BDX

Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

$225.53
-2.23 (-0.98%)
(As of 07/8/2024 ET)
Today's Range
$225.19
$228.55
50-Day Range
$224.93
$240.63
52-Week Range
$224.00
$287.32
Volume
826,404 shs
Average Volume
1.43 million shs
Market Capitalization
$65.18 billion
P/E Ratio
49.68
Dividend Yield
1.68%
Price Target
$280.86

Becton, Dickinson and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
24.5% Upside
$280.86 Price Target
Short Interest
Healthy
0.68% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.48
Upright™ Environmental Score
News Sentiment
0.74mentions of Becton, Dickinson and Company in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.03 M Sold Last Quarter
Proj. Earnings Growth
9.05%
From $13.04 to $14.22 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.89 out of 5 stars

Medical Sector

34th out of 876 stocks

Surgical & Medical Instruments Industry

6th out of 94 stocks

BDX stock logo

About Becton, Dickinson and Company Stock (NYSE:BDX)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

BDX Stock Price History

BDX Stock News Headlines

Next hot AI projects are NOT on the Nasdaq
Nearly 9 out of 10 Americans totally ignore this market. And you’ll probably never hear your broker mention it.
Next hot AI projects are NOT on the Nasdaq
Nearly 9 out of 10 Americans totally ignore this market. And you’ll probably never hear your broker mention it.
Piper Sandler Keeps Their Buy Rating on Becton Dickinson (BDX)
See More Headlines
Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Becton, Dickinson and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Ex-Dividend for 6/28 Dividend
6/10/2024
Dividend Payable
6/28/2024
Today
7/09/2024
Next Earnings (Confirmed)
8/01/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
07588710
Employees
73,000
Year Founded
1897

Price Target and Rating

Average Stock Price Target
$280.86
High Stock Price Target
$312.00
Low Stock Price Target
$260.00
Potential Upside/Downside
+24.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$1.48 billion
Pretax Margin
8.34%

Debt

Sales & Book Value

Annual Sales
$19.37 billion
Cash Flow
$20.03 per share
Book Value
$88.92 per share

Miscellaneous

Free Float
288,110,000
Market Cap
$65.18 billion
Optionable
Optionable
Beta
0.42

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

  • Becton, Dickinson and Company has a strong market capitalization of $67.56 billion, indicating stability and financial strength.
  • The company's stock has a relatively low beta of 0.44, suggesting lower volatility compared to the market average.
  • Analysts have given the stock a consensus rating of "Moderate Buy" with an average target price of $280.17, indicating positive sentiment and potential for growth.
  • Becton, Dickinson and Company's 50-day simple moving average of $234.89 is close to the current stock price of $233.78, showing stability in recent trading patterns.
  • Recent insider transactions show executives selling shares, which could be seen as a positive sign of confidence in the company's performance.

Cons

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

  • The company's price-to-earnings ratio of 51.49 is relatively high, indicating that the stock may be overvalued compared to its earnings.
  • Becton, Dickinson and Company's 52-week high of $287.32 suggests that the stock may have limited room for significant short-term price appreciation.
  • The debt-to-equity ratio of 0.62 may raise concerns about the company's leverage and financial risk.
  • The stock's 200-day simple moving average of $237.89 is below the current stock price, potentially signaling a negative trend in the medium term.
  • Insiders selling a significant number of shares over the last three months could be interpreted as a lack of confidence in the company's future prospects.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 30, 2024. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

BDX Stock Analysis - Frequently Asked Questions

How have BDX shares performed this year?

Becton, Dickinson and Company's stock was trading at $243.83 on January 1st, 2024. Since then, BDX stock has decreased by 7.5% and is now trading at $225.53.
View the best growth stocks for 2024 here
.

How were Becton, Dickinson and Company's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) issued its quarterly earnings data on Thursday, May, 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. The firm's revenue was up 4.6% compared to the same quarter last year.
Read the conference call transcript
.

What is Tom Polen's approval rating as Becton, Dickinson and Company's CEO?

136 employees have rated Becton, Dickinson and Company Chief Executive Officer Tom Polen on Glassdoor.com. Tom Polen has an approval rating of 91% among the company's employees. This puts Tom Polen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Becton, Dickinson and Company have any subsidiaries?

Becton, Dickinson and Company subsidiaries include these companies: Cytognos, Scanwell Health Inc., Tissuemed Ltd., Venclose Inc., Tepha Inc., Velano Vascular, GSL Solutions, and others.

Who are Becton, Dickinson and Company's major shareholders?

Becton, Dickinson and Company's top institutional shareholders include Rempart Asset Management Inc. (0.03%), Confluence Investment Management LLC (0.03%), DNB Asset Management AS (0.02%) and ST Germain D J Co. Inc. (0.02%). Insiders that own company stock include Thomas E Polen Jr, Claire Fraser, Roland Goette, Samrat S Khichi, Michael David Garrison, David Hickey, Richard Byrd, Rebecca W Rimel, Thomas J Spoerel, Alexandre Conroy, Betty D Larson and James C Lim.
View institutional ownership trends
.

How do I buy shares of Becton, Dickinson and Company?

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Becton, Dickinson and Company own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Becton, Dickinson and Company investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), Walt Disney (DIS), Abbott Laboratories (ABT) and Intel (INTC).

This page (NYSE:BDX) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners